Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Get Supernus Pharmaceuticals alerts:Read Our Latest Stock Analysis on SUPNSupernus Pharmaceuticals Price PerformanceInstitutional Inflows and OutflowsShares of SUPN opened at $47.64 on Thursday. Further ReadingReceive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.